The Dana-Farber Cancer Institute (DFCI)’s MatchMiner tool was developed to increase historically low clinical trial enrollment rates in adults with cancer. Roy Perlis, MD, MSc, Editor in Chief of JAMA+ AI, spoke with Kenneth Kehl, MD, MPH, about his recent study published in JAMA Network Open evaluating the AI tool’s ability to fulfill its purpose through genome sequencing. Related Content: Clinical Trial Notifications Triggered by Artificial Intelligence–Detected Cancer Progression Considerations in Translating AI to Improve Care How AI Could Increase Clinical Trial Enrollment in Adults With Cancer

Ver todos los episodios